Genetic Resourcesとは 意味・読み方・使い方

With regard to an invention-creation accomplished by relying on genetic resources, the applicant shall, in the patent application documents, indicate the direct and original source of the genetic resources.発音を聞く 例文帳に追加

遺伝資源に依存して完成した発明創造について、出願者は特許出願書類において当該遺伝資源の直接的由来と原始的由来を説明する。 - 特許庁

The protocol establishes guidelines for access to genetic resources and the fair and equitable sharing of benefits arising from their utilization.発音を聞く 例文帳に追加

この議定書は，遺伝資源の利用権やそれらの利用から生じる利益の公正かつ衡平な配分に関するガイドラインを定めている。 - 浜島書店 Catch a Wave

In addition, while its pharmaceutical and biotech industry is small-scaled as of now, the government of India is committed to fostering these industries that would make use of the country’s strengths—such as human resources and skills, diverse biological genetic resources, etc.例文帳に追加

その他、バイオ・医薬品産業の現時点での産業規模は小さいものの、インドの強みである人材・技術、生物遺伝資源における多様性等を生かせる産業としてインド政府は育成に力を注いでいる。 - 経済産業省

Patent rights shall not be granted for inventions that are accomplished by relying on genetic resources which are obtained or used in violation of the provisions of laws and administrative regulations.発音を聞く 例文帳に追加

法律と行政法規の規定に違反して遺伝資源を獲得し、または利用し、当該遺伝資源に依存して完成したりした発明創造に対しては、特許権を付与しない。 - 特許庁

If access to biological material has been provided in pursuance of Article 12.2 and Article 12.3 of the International Treaty of 3 November, 2001 on Plant Genetic Resources for Food and Agriculture, a copy of the standard material transfer agreement (MTA) stipulated in Article 12.4 of the Treaty shall be enclosed with the patent application instead of the information stipulated in the first and second paragraphs.例文帳に追加

2001年11月3日の食料農業植物遺伝資源国際条約第12.2条及び第12.3条に基づいて生物学的材料を入手した場合は，同条約第12.4条に定める標準材料移転契約(MTA)の写しを第1段落及び第2段落に規定する情報の代わりに，特許出願に同封する。 - 特許庁

In 2006, discussions were held at meetings of the TRIPS Council and under the auspices of the WTO Deputy Director-General. Some developing countries, such as India, Brazil and Peru, argue that the TRIPS Agreement should be amended to include a disclosure requirement of source and country of origin of genetic resources, prior informed consent to the use of genetic resources and provisions evidencing fair and equitable benefit sharing in order to obligate disclosure of such information in patent applications. To the contrary, Japan, the US and other countries find no conflict between the TRIPS Agreement and the CBD, and believe that it is possible to apply the two agreements in a mutually supportive manner. Therefore, there is a large gap between those countries that believe that amendment of the TRIPS Agreement is unnecessary in order to achieve the purpose of the CBD and those countries that believe it is necessary. Discussions have not converged yet.例文帳に追加

2006年には、TRIPS 理事会、WTO事務局次長主催の協議の場等において議論が行われたが、遺伝資源等の出所や原産国、遺伝資源等の利用にかかる事前の同意、及び公正かつ衡平な利益配分の証拠につき、特許出願中に開示を義務づけるため、TRIPS 協定を改正するよう求めるインド、ブラジル、ペルー等の諸国と、我が国、米国等、TRIPS 協定とCBD は抵触なく、相互補完的に履行可能であり、CBD の目的を達成するに当たってTRIPS 協定の改正は不要とする諸国との間に意見の隔たりが大きく、議論の収束には至っていない。 - 経済産業省

Further, the “promotion program for intellectual property 2007” stated that operation status of patent criteria on technology of “how to produce the effect-efficacy of pharmaceutical drugs for manufacturing and selling of the pharmaceutical drugs” revised in April, 2005 should be observed and that continuous collection and analysis of information should be provided on the technology trend in the advanced medical field as well as the trends of international discussion regarding the patent protection since 2007. Furthermore, the same program includes reinforcement of the investigation system related to intellectual property policies (such as policies for genetic resources) and also includes investigations related to arrangement of the rules to restrict author's rights on the occasion for the drug manufacturer/distributor to provide formation related to proper use of drugs, etc. to healthcare professionals.例文帳に追加

また、「知的財産推進計画 2007」においては、2005 年 4 月に改訂された「医薬の製造・販売のために医薬の新しい効能・効果を発現させる方法」の技術に係る特許審査基準の運用状況等を注視すること、2007 年度以降、先端医療分野における技術動向やその特許保護に関する国際的な議論の動向について、継続的な情報の収集、分析に努めることとされた。さらに、同計画には、遺伝資源等の国際的な知財政策に関する検討体制の強化や、医薬品等の製造販売業者が医薬関係者に医薬品等の適正使用に必要な情報提供を行う際の著作権の権利制限規定の整備に関する検討等についても盛り込まれた。 - 厚生労働省